NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are probably relishing these truly exciting times after a Chicago-based institutional investor committed to fund $27 million dollars toward the company's clinical trials in advanced inoperable pancreatic cancer. Leading up to the aforementioned clinical trials, investors can expect to see a list of milestone developments unfold, and for those who consider themselves biotech junkies, they know this is when the fun begins.
Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.
NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Nuvilex, Inc. (NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the company also has a medical marijuana subsidiary slated to begin cancer research and development using cannabidiol. With each of the key target markets representing multi-billion-dollar opportunities, Nuvilex offers investors multiple opportunities for success and should trade at a valuation that reflects its current development progress to date.
NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million "pot of money" to advance the company's late-phase pancreatic cancer clinical trials. Notice we said restricted shares, that's right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex. But, is this investment really a risk? It appears the Chicago-based firm knows exactly what the future could hold for Nuvilex, and they're comfortable with paying a premium price to become a long-term investor right along with many others who believe in the small biotechnology firm.
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials
NEW YORK, NY--(Marketwired - Feb 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
Nuvilex Announces $27 Million Funding Commitment With Institutional Investor to Advance Late Phase Clinical Trials
$2 Million Initial Investment Completed
SILVER SPRING, Md., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of Nuvilex's common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of Nuvilex, up to an additional $25 million of equity capital over the term of the purchase agreement. The proceeds from this investment will be used for Nuvilex's late-stage clinical trials in advanced inoperable pancreatic cancer, for research into the use of constituents of marijuana in the emerging medical marijuana arena and for general operating purposes.
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company's pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than were seen with this same combination in two earlier independent Phase II trials, then not only will it be mentioned with those larger companies, Nuvilex's treatment will likely be the new "gold standard" for the disease.
NEW YORK, NY--(Marketwired - Feb 14, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) Dr. Mark L. Rabe has something in common with 18 members of Congress. All of them want marijuana reclassified from its current listing as a dangerous drug with no medical value, and they want President Obama to use his authority to make that change by removing marijuana from the Schedule I category. Currently marijuana is viewed in the same category as drugs like heroin and LSD, and in a letter sent to the president this week, 18 legislators said this status "makes no sense."
NEW YORK, NY--(Marketwired - Feb 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a biotechnology company that's focused on getting into late phase clinical trials for the treatment of advanced, inoperable pancreatic cancer, but it also expects to be a major player in the medical marijuana arena. And, to that end, last December, Nuvilex landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe. Dr. Rabe was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS), the wholly-owned subsidiary Nuvilex formed to house its work in the Cannabis industry.
NEW YORK, NY--(Marketwired - Feb 10, 2014) - If Nuvilex, Inc. (OTCQB: NVLX) can use the Cell-in-a-Box™ technology to develop marijuana-based treatments for cancer with the same success it has seen in two independent clinical trials to develop a treatment for advanced inoperable pancreatic cancer, then the Cannabis industry is in for some real fireworks.
NEW YORK, NY--(Marketwired - Feb 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) entered the medical marijuana arena in 2013 as a biotech that would use its expertise to develop treatments for hard to treat cancers. The company said it will initially utilize cannabidiol, one of the compounds found in Cannabis, as the basis for developing treatments for some of the deadliest forms of cancer, namely pancreatic cancer and cancers of the brain, that have historically shown they're extremely difficult to treat.